We are going through some challenges as Coronavirus spreads all over the world.It makes sense for us to be braced and have knowledge on best approaches to help our body fight the virus, in case it will be needed. We put together several informations and research content about supplements that can help fighting virus infections for you.



It is used to treat Myelofibrosis and Polycythaemia vera. Polycythemia vera is a rare, chronic blood cancer where the bone marrow produces too many red blood cells. Myelofibrosis is also a rare, chronic blood cancer. It can also “progress,” or get worse over time. For example, new symptoms may appear or existing symptoms may get worse.

Method of administration

Licensed for

  • Hepatitis C

  • Hepatitis B

  • Melanoma

  • AIDS related diseases

Licensed dose

The licensed dose for IFN-α2b is once a week. In adults, used in combination treatments at a dose of 1.5 mg per kg body weight, or on its own at 0.5 or 1.0 mg/kg. The treatment duration is from 6 months to a year. But the dose and duration of treatment depends on the disease being treated and the response of the patient.

Status of clinical development for Coronaviruses

Ruxolitinib is currently clinically trialled for COVID-19. In the clinical study of MERS with a retrospectiveobservational study and 349 patients, there was no decrease in mortality nor faster virus RNA clearance.

Proposed dose for COVID-19

The dosage for clinical trail of COVID-19 is currently not available. But the purposed dose for MERS-patients is 1.5mcg/kg subcutaneously once per for 2 weeks.

Go back to the overview